OPRM1 rs1799971 polymorphism and opioid dependence: Evidence from a meta-analysis

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 813-824

  Haerian, Batoul Sadat ^a   Haerian, Monir Sadat ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

heroin; meta analysis; opioid dependence; polymorphism

Indexed keywords

MU OPIATE RECEPTOR; OPIATE;

ASIAN; AUTOSOMAL DOMINANT INHERITANCE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; EXON; GENE; HEROIN DEPENDENCE; HUMAN; META ANALYSIS (TOPIC); OPIATE ADDICTION; OPRM1 GENE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ANALGESICS, OPIOID; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HEROIN DEPENDENCE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; RISK FACTORS;

EID: 84877653005     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.57     Document Type: Review

References (45)

1. Sawynok J. The therapeutic use of heroin: a review of the pharmacological literature. Can. J. Physiol. Pharmacol. 64, 1-6 (1986).
2. Goldstein FJ. Adjuncts to opioid therapy. J. Am. Osteopath. Assoc. 102, S15-S21 (2002).
3. Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict. Sci. Clin. Pract. 4, 4-25 (2008).
4. Ikeda K, Ide S, Han W, et al. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol. Sci. 26(6), 311-317 (2005).
5. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 6, 521-532 (2005).
6. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66, 285-306 (2002).
7. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 410, 249-268 (2000).
8. Yuferov V, Levran O, Proudnikov D, et al. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann. NY Acad. Sci. 1187, 184-207 (2010).
9. Kreek MJ, Bart G, Lilly C, et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev. 57, 1-26 (2005).
10. Kasai S, Ikeda K. Pharmacogenomics of the human μ-opioid receptor. Pharmacogenomics 12, 1305-1320 (2011).
11. Oertel BG, Doehring A, Roskam B, et al. Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum. Mol. Genet. 21, 4751-4760 (2012).
12. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human μ opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608-9613 (1998).
13. Gelernter J, Kranzler H, Cubells J. Genetics of two μ opioid receptor gene (OPRM1) exon 1 polymorphisms: population studies, and allele frequencies in alcohol-and drug-dependent subjects. Mol. Psychiatry 4, 476-483 (1999).
14. Li T, Liu X, Zhu Z, et al. Association analysis of polymorphisms in the μ opioid gene and heroin abuse in Chinese. Addict. Biol. 5, 181-186 (2000).
15. Szeto CY, Tang NL, Lee DT, et al. Association between μ opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 12, 1103-1106 (2001).
16. Franke P, Wang T, Nöthen MM, et al. Nonreplication of association between μ-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am. J. Med. Genet. 105(1), 114-119 (2001).
17. Shi J, Hui L, Xu Y, et al. Sequence variations in the μ-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum. Mutat. 19(4), 459-460 (2002).
18. Tan EC, Tan CH, Karupathivan U, et al. μ opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 14, 569-572 (2003).
19. Luo X, Kranzlet HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am. J. Med. Genet. 120B, 97-108 (2003).
20. Crowley JJ, Oslin DW, Patkar AA, et al. A genetic association study of the μ opioid receptor and severe opioid dependence. Psychiatr. Genet. 13, 169-173 (2003).
21. Bart G, Heilig M, LaForge KS, et al. Substantial attributable risk related to a functional μ-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 9, 547-549 (2004).
22. Drakenberg K, Nikoshkov A, Horváth MC, et al. μ opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc. Natl Acad. Sci. USA 103, 7883-7888 (2006).
23. Zhang H, Luo X, Kranzler HR, et al. Association between two μ-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Genet. 15(6), 807-819 (2006).
24. Zhang D, Shao C, Shao M, et al. Effect of μ-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol. Psychiatry 61(11), 1244-1251 (2007).
25. Kapur S, Sharad S, Singh RA, Gupta AK. A118G polymorphism in μ opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J. Integr. Neurosci. 6(4), 511-522 (2007).
26. Deb I, Chakraborty J, Gangopadhyay PK, et al. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by μ-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 112, 486-496 (2010).
27. Nikolov MA, Beltcheva O, Galabova A, et al. No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. Drug Alcohol Depend. 117(1), 62-65 (2011).
28. Kumar D, Chakraborty J, Das S. Epistatic effects between variants of k-opioid receptor gene and A118G of μ-opioid receptor gene increase susceptibility to addiction in Indian population. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 225-230 (2012).
29. Nagaya D, Ramanathan S, Ravichandran M, et al. A118G μ opioid receptor polymorphism among drug addicts in Malaysia. J. Integr. Neurosci. 11, 117-122 (2012).
30. Swartz MK. The PRISMA statement: a guideline for systematic reviews and meta-analyses. J. Pediatr. Health Care 25, 1-2 (2011).
31. Bax L, Yu LM, Ikeda N, et al. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med. Res. Methodol. 6, 1-11 (2006).
32. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 83(3), 262-268 (2006).
33. Glatt SJ, Bousman C, Wang RS, et al. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend. 90(2-3), 159-165 (2007).
34. Coller JK, Beardsley J, Bignold J, et al. Lack of association between the A118G polymorphism of the μ opioid receptor gene (OPRM1) and opioid dependence: a meta-analysis. Pharmgenomics Pers. Med. 2, 9-19 (2009).
35. Kreek MJ, LaForge KS. Stress responsivity, addiction, and a functional variant of the human μ-opioid receptor gene. Mol. Interv. 7, 74-78 (2007).
36. Uhl GR, Sora I, Wang Z. The μ opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc. Natl Acad. Sci. USA 96, 7752-7755 (1999).
37. Ramchandani VA, Umhau J, Pavon FJ, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16, 809-817 (2011).
38. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc. Natl Acad. Sci. USA 106(26), 10847-10852 (2009).
39. Wang YJ, Huang P, Ung A, et al. Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience 205, 178-184 (2012).
40. Ducci F, Goldman D. The genetic basis of addictive disorders. Psychiatr. Clin. N. Am. 35(2), 495-519 (2012).
41. Sabeti PC, Schaffner SF, Fry B, et al. Positive natural selection in the human lineage. Science 312(5780), 1614-1620 (2006).
42. Spencer CC, Su Z, Donnelly P, et al. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 5, e1000477 (2009).
43. Minelli C, Thompson JR, Abrams KR, et al. How should we use information about HWE in the meta-analyses of genetic association studies? Int. J. Epidemiol. 37, 136-146 (2008).
44. Zintzaras E. Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur. J. Epidemiol. 25, 553-560 (2010).
45. Vine AE, Curtis D. Markers typed in genome-wide analysis identify regions showing deviation from Hardy-Weinberg equilibrium. BMC Res. Notes 2, 29 (2009).